AbbVie (ABBV) Leerink Global Healthcare Conference 2026 summary

Growth outlook and financial performance

• Guidance targets $67 billion in 2026 revenue, with high single-digit growth projected through the decade.

• SKYRIZI and RINVOQ drive over 20% combined growth, with significant market share headroom in immunology.

• Neuroscience is the second fastest-growing area, with migraine and Parkinson's franchises expected to exceed $5 billion each in peak sales.

• Operating margin expansion continues, with EPS growth over 13% and ongoing SG&A efficiencies.

• R&D investment remains at 14%-15% of sales, increasing by several billion dollars since 2022.

Competitive positioning and product updates

• SKYRIZI holds over 60% of new IBD patient starts and 75% in first-line naive patients, with further growth expected.

• Subcutaneous SKYRIZI data shows improved efficacy, with regulatory submission planned in the coming months and anticipated approval and launch early next year.

• RINVOQ label update in Q3 last year allows second-line use post-biologic failure, supporting expanded use.

• Dual portfolio approach in IBD enhances competitive positioning against emerging therapies.

Pipeline and upcoming catalysts

• Amylin candidate shows nearly 10% weight loss at 12 weeks in a non-obese, mostly male population, with phase Ib and II trials planned in higher BMI patients.

• Multiple phase III readouts expected this year for RINVOQ and lutikizumab in hidradenitis suppurativa (HS), with potential for multi-billion dollar peak sales.

• Combination studies in IBD and new B-cell depletion therapies will yield data this year.

• Oncology pipeline includes phase III readouts for BCMA antibody in multiple myeloma and next-gen ADCs in ovarian, lung, and colorectal cancers.

• Neuroscience readouts include phase II data for bretasilocin in depression and migraine franchise expansion.